432 related articles for article (PubMed ID: 36059621)
1. Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
Muylaert C; Van Hemelrijck LA; Maes A; De Veirman K; Menu E; Vanderkerken K; De Bruyne E
Front Oncol; 2022; 12():979569. PubMed ID: 36059621
[TBL] [Abstract][Full Text] [Related]
2. The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response.
De Smedt E; Lui H; Maes K; De Veirman K; Menu E; Vanderkerken K; De Bruyne E
Front Oncol; 2018; 8():566. PubMed ID: 30619733
[TBL] [Abstract][Full Text] [Related]
3. Role of epigenetics-microRNA axis in drug resistance of multiple myeloma.
Rastgoo N; Abdi J; Hou J; Chang H
J Hematol Oncol; 2017 Jun; 10(1):121. PubMed ID: 28623912
[TBL] [Abstract][Full Text] [Related]
4. The Role of Epigenetics in the Development and Progression of Multiple Myeloma.
Ismail NH; Mussa A; Zakaria NA; Al-Khreisat MJ; Zahidin MA; Ramli NN; Mohammad SNNA; Hassan R; Mohd Noor NH; Iberahim S; Zulkafli Z; Mohamed Yusoff S; Husin A; Johan MF
Biomedicines; 2022 Oct; 10(11):. PubMed ID: 36359286
[TBL] [Abstract][Full Text] [Related]
5. Epigenetics in multiple myeloma: From mechanisms to therapy.
Alzrigat M; Párraga AA; Jernberg-Wiklund H
Semin Cancer Biol; 2018 Aug; 51():101-115. PubMed ID: 28962927
[TBL] [Abstract][Full Text] [Related]
6. Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse.
Krzeminski P; Corchete LA; García JL; López-Corral L; Fermiñán E; García EM; Martín AA; Hernández-Rivas JM; García-Sanz R; San Miguel JF; Gutiérrez NC
Oncotarget; 2016 Dec; 7(49):80664-80679. PubMed ID: 27811368
[TBL] [Abstract][Full Text] [Related]
7. An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.
Holm K; Staaf J; Lauss M; Aine M; Lindgren D; Bendahl PO; Vallon-Christersson J; Barkardottir RB; Höglund M; Borg Å; Jönsson G; Ringnér M
Breast Cancer Res; 2016 Feb; 18(1):27. PubMed ID: 26923702
[TBL] [Abstract][Full Text] [Related]
8. Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications.
Schütt J; Nägler T; Schenk T; Brioli A
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439223
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Regulation in Oral Squamous Cell Carcinoma Microenvironment: A Comprehensive Review.
Mesgari H; Esmaelian S; Nasiri K; Ghasemzadeh S; Doroudgar P; Payandeh Z
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067304
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.
Furukawa Y; Kikuchi J
Int J Hematol; 2016 Sep; 104(3):281-92. PubMed ID: 27411688
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation.
Amodio N; D'Aquila P; Passarino G; Tassone P; Bellizzi D
Expert Opin Ther Targets; 2017 Jan; 21(1):91-101. PubMed ID: 27892767
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance in multiple myeloma.
Robak P; Drozdz I; Szemraj J; Robak T
Cancer Treat Rev; 2018 Nov; 70():199-208. PubMed ID: 30245231
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.
Maes K; Menu E; Van Valckenborgh E; Van Riet I; Vanderkerken K; De Bruyne E
Cancers (Basel); 2013 Apr; 5(2):430-61. PubMed ID: 24216985
[TBL] [Abstract][Full Text] [Related]
14. Compendium of aberrant DNA methylation and histone modifications in cancer.
Hattori N; Ushijima T
Biochem Biophys Res Commun; 2014 Dec; 455(1-2):3-9. PubMed ID: 25194808
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer.
Sharma A; Heuck CJ; Fazzari MJ; Mehta J; Singhal S; Greally JM; Verma A
Wiley Interdiscip Rev Syst Biol Med; 2010; 2(6):654-69. PubMed ID: 20890963
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
Dupéré-Richer D; Licht JD
Curr Opin Hematol; 2017 Jul; 24(4):336-344. PubMed ID: 28441149
[TBL] [Abstract][Full Text] [Related]
17. Epigenetics in cancer: targeting chromatin modifications.
Ellis L; Atadja PW; Johnstone RW
Mol Cancer Ther; 2009 Jun; 8(6):1409-20. PubMed ID: 19509247
[TBL] [Abstract][Full Text] [Related]
18. DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma.
Alberge JB; Magrangeas F; Wagner M; Denié S; Guérin-Charbonnel C; Campion L; Attal M; Avet-Loiseau H; Carell T; Moreau P; Minvielle S; Sérandour AA
Clin Epigenetics; 2020 Nov; 12(1):163. PubMed ID: 33138842
[TBL] [Abstract][Full Text] [Related]
19. Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma.
Herviou L; Ovejero S; Izard F; Karmous-Gadacha O; Gourzones C; Bellanger C; De Smedt E; Ma A; Vincent L; Cartron G; Jin J; De Bruyne E; Grimaud C; Julien E; Moreaux J
Clin Epigenetics; 2021 Sep; 13(1):174. PubMed ID: 34530900
[TBL] [Abstract][Full Text] [Related]
20. Germline Risk Contribution to Genomic Instability in Multiple Myeloma.
Janz S; Zhan F; Sun F; Cheng Y; Pisano M; Yang Y; Goldschmidt H; Hari P
Front Genet; 2019; 10():424. PubMed ID: 31139207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
